Novo Nordisk A/S (NVO) to Issue Semi-Annual Dividend of $0.32 on August 27th

Novo Nordisk A/S (NYSE:NVO) announced a Semi-Annual dividend on Friday, August 9th, NASDAQ reports. Shareholders of record on Monday, August 19th will be paid a dividend of 0.318 per share on Tuesday, August 27th. The ex-dividend date is Friday, August 16th.

Novo Nordisk A/S has raised its dividend by an average of 19.3% annually over the last three years. Novo Nordisk A/S has a dividend payout ratio of 44.0% indicating that its dividend is sufficiently covered by earnings. Analysts expect Novo Nordisk A/S to earn $2.81 per share next year, which means the company should continue to be able to cover its $1.11 annual dividend with an expected future payout ratio of 39.5%.

NYSE NVO traded down $0.89 during midday trading on Wednesday, hitting $50.97. 8,372 shares of the company traded hands, compared to its average volume of 1,426,194. Novo Nordisk A/S has a 52 week low of $41.23 and a 52 week high of $52.83. The firm has a 50-day simple moving average of $49.53. The company has a current ratio of 0.96, a quick ratio of 0.66 and a debt-to-equity ratio of 0.07. The stock has a market capitalization of $123.15 billion, a P/E ratio of 20.18, a PEG ratio of 2.30 and a beta of 0.60.



Several brokerages have recently commented on NVO. Credit Suisse Group upgraded Novo Nordisk A/S from a “neutral” rating to an “outperform” rating in a report on Monday, April 29th. Zacks Investment Research upgraded Novo Nordisk A/S from a “sell” rating to a “hold” rating and set a $50.00 price objective for the company in a report on Monday, July 15th. Barclays upgraded Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $51.85 price objective for the company in a report on Tuesday, June 11th. UBS Group reiterated a “buy” rating and set a $355.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, June 19th. Finally, Deutsche Bank lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $52.42 price objective for the company. in a report on Thursday, June 20th. One analyst has rated the stock with a sell rating, ten have assigned a hold rating and six have issued a buy rating to the stock. Novo Nordisk A/S currently has a consensus rating of “Hold” and a consensus price target of $111.58.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.

Featured Article: What does relative strength index mean?

Dividend History for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.